Study on the Molecular Mechanism of Stephania Terandra in the Therapy for Hypertension Based on Inte-grated Pharmacology Platform
- VernacularTitle:基于整合药理学平台的中药防己治疗高血压分子机制研究
- Author:
Yanying ZHANG
1
;
Na LI
;
Guoqi LIU
;
Zhenying ZHAO
Author Information
1. 营口经济技术开发区中心医院药剂科 辽宁营口115007
- Keywords:
Hypertension;
Stephania terandra;
Integrated pharmacology
- From:
China Pharmacist
2018;21(10):1716-1720
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the potential genetic target of Stephania terandra in the therapy for hypertension based on inte-grated pharmacology platform to study the molecular mechanism of Chinese medicines in treating hypertension. Methods: Using the functional prediction modules of integrated pharmacology platform and the functional modules of network construction, the component-target network of Stephania terandra was calculated, and the target network of anti-hypertension was further calculated, and the target molecules related to hypertension were explored. Results: A total of 198 targets related to hypertension were obtained from the hyper-tension prevention. Among them, there were 59 potential action nodes and 20 known action nodes. The nodes with direct action were type-2 angiotensin Ⅱ receptor ( AGTR2), type-1 angiotensin Ⅱ receptor ( AGTR1), prostacyclin receptor ( PTGIR), solute carrier family 12 member 3 (SLC12A3) and endothelin-1 (EDN1). The GO enrichment and KEGG pathway enrichment of Stephania terandra chemical components showed a close correlation with hypertension, and the molecular mechanism of the target was clear. Conclusion:Through the integration of pharmacology platform, the targets of Stephania terandra-disease are deeply explored, and its potential mo-lecular mechanism as well as potential factors is studied.
